依杜沙班
医学
心房颤动
华法林
冲程(发动机)
蒂米
内科学
心脏病学
重症监护医学
临床试验
拜瑞妥
经皮冠状动脉介入治疗
心肌梗塞
机械工程
工程类
作者
C. Escobar Cervantes,José Luís Merino,Vivencio Barrios
标识
DOI:10.1080/14779072.2019.1598263
摘要
Introduction: Edoxaban is the last direct oral anticoagulant marketed for the prevention of stroke among patients with nonvalvular atrial fibrillation (AF).Areas covered: ENGAGE AF–TIMI 48 was the pivotal clinical trial that led to the approval of edoxaban 60 mg once daily. After the publication of this study, a great number of substudies and post hoc analyses have been published, together with some observational studies. The aim of this review was to update the current evidence about the use of edoxaban in AF patients.Expert opinion: In the ENGAGE AF–TIMI 48 trial, edoxaban 60 mg was noninferior to warfarin for the prevention of stroke or systemic embolism, but significantly reduced the risk of bleeding, major adverse cardiac events and death from cardiovascular causes. The relative efficacy and safety of edoxaban 60 mg compared with warfarin were independent of different clinical conditions, such as prior stroke, age, risk of falls, renal function, hepatic disease, ischemic heart disease, heart failure, valvular heart disease, or cancer. Data about the effectiveness and safety of edoxaban in real-life patients are scarce, but consistent with those of the pivotal clinical trial. Edoxaban seems a cost-effective alternative to warfarin among AF patients with moderate to high thromboembolic risk.
科研通智能强力驱动
Strongly Powered by AbleSci AI